SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
197 hedge funds and large institutions have $477M invested in SANGAMO THERAPEUTICS INC in 2022 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 23 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 46
39% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 23
29% more capital invested
Capital invested by funds: $370M → $477M (+$107M)
24% more call options, than puts
Call options by funds: $2.45M | Put options by funds: $1.97M
5% more funds holding
Funds holding: 188 → 197 (+9)
1.07% more ownership
Funds ownership: 61.14% → 62.21% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$12.1M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.6M |
| 3 |
BlackRock
New York
|
+$9.75M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.19M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$3.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Casdin Capital
New York
|
-$4.14M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.96M |
| 3 |
Millennium Management
New York
|
-$2.98M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.03M |
| 5 |
Morgan Stanley
New York
|
-$1.65M |
SGMO Hedge Fund Activity: Q3 2022 in Review
197 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2022, worth a combined $477M — up 29% from $370M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SGMO positions and 23 closed out — a net gain of 9 holders — while 68 added to existing stakes and 46 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $12.1M. The largest seller was Casdin Capital, exiting entirely with an estimated $4.14M sold.
- 197 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2022, up from 188 in Q2 2022.
- Funds reported $477M of SANGAMO THERAPEUTICS INC stock for Q3 2022, up 29% quarter-over-quarter.
- 32 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2022 and 23 closed out, a net change of +9 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2022 was Avidity Partners Management, an estimated $12.1M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2022 was Casdin Capital, an estimated $4.14M sold.
Based on aggregated 13F filings for Q3 2022.